180 Life Sciences Corp
NASDAQ:ATNF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
180 Life Sciences Corp
NASDAQ:ATNF
|
US |
|
Tempus Resources Ltd
ASX:TMR
|
AU |
|
Bank Victoria International Tbk PT
IDX:BVIC
|
ID |
180 Life Sciences Corp
180 Life Sciences Corp. develops pharmaceuticals for chronic pain and inflammatory diseases. The company is headquartered in Menlo Park, California and currently employs 7 full-time employees. The company went IPO on 2017-06-07. The firm is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by research and combination therapy. The Company’s programs developing novel drugs for treating distinct inflammatory diseases. The firm has three product development platforms Anti-TNF platform, SCAs platform and α7nAChR platform. The Anti-TNF platform is focused on the fibrosis and anti-tumor necrosis factor (anti-TNF). The SCAs platform is focused on the drugs that are synthetic cannabidiol (CBD) or cannabigerol (CBG) analogues (SCAs). The α7nAChR platform, which is focused on the alpha 7 nicotinic acetylcholine receptor (α7nAChR). The firm is conducting clinical trials only for certain indications under the anti-TNF platform. The firm is also undertaking preclinical research and development activities for the SCA and the α7nAChR platforms.
180 Life Sciences Corp. develops pharmaceuticals for chronic pain and inflammatory diseases. The company is headquartered in Menlo Park, California and currently employs 7 full-time employees. The company went IPO on 2017-06-07. The firm is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by research and combination therapy. The Company’s programs developing novel drugs for treating distinct inflammatory diseases. The firm has three product development platforms Anti-TNF platform, SCAs platform and α7nAChR platform. The Anti-TNF platform is focused on the fibrosis and anti-tumor necrosis factor (anti-TNF). The SCAs platform is focused on the drugs that are synthetic cannabidiol (CBD) or cannabigerol (CBG) analogues (SCAs). The α7nAChR platform, which is focused on the alpha 7 nicotinic acetylcholine receptor (α7nAChR). The firm is conducting clinical trials only for certain indications under the anti-TNF platform. The firm is also undertaking preclinical research and development activities for the SCA and the α7nAChR platforms.
